Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Nektar TherapeuticsNASDAQ: NKTR

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $347K.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, down 31.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $86.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$347K-97.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.2% is the 6th highest of 8, against a peer median of -18.4%.
  • Cost of revenue amounts to 0.6% of revenue for NKTR, versus a peer median of 6.0%.
NKTR Competitors
Cost of Revenue for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
CHRSCoherus Oncology, Inc.LTM Mar 2026$18.73M USD-78.7%-36.7%40.0%
CGENCompugen Ltd.LTM Mar 2026$8.68M USD+5.4%+111.7%11.9%
RCUSArcus Biosciences, Inc.LTM Jun 2026$7M USD——6.0%
IMCRImmunocore Holdings plcLTM Mar 2026$4.61M USD+39.0%+5.5%1.2%
NKTRNektar TherapeuticsLTM Jun 2026$347K USD-97.2%—0.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$55K USD———
IMTXImmatics N.V.LTM Mar 2026€0 EUR-100.0%—0.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD——0.0%
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding NKTR) —-18.4%+5.5%6.0%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.